75,000 CervoMed (CRVO) stock options granted to CEO’s spouse
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
CervoMed Inc. reported an indirect insider award linked to director and 10% owner Sylvie Gregoire. A derivative position of 75,000 stock options with a $4.80 exercise price was granted on February 11, 2026 to her spouse, John Alam, the company’s President & Chief Executive Officer.
The options relate to 75,000 shares of common stock and were reported at a cost of $0 for the derivative itself, with 75,000 derivative securities beneficially owned after the transaction as indirect ownership "By Spouse." The filing states that Gregoire disclaims beneficial ownership. The underlying shares will vest in 36 monthly installments beginning February 28, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Gregoire Sylvie
Role
Director, 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 75,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 75,000 shares (Indirect, By Spouse)
Footnotes (1)
- Consists of an option to purchase shares of common stock granted to John Alam, M.D., the Reporting Person's spouse and the President & Chief Executive Officer of the Issuer and a member of its Board of Directors. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026.
FAQ
What insider transaction did CervoMed (CRVO) disclose in this Form 4?
CervoMed disclosed a grant of 75,000 stock options with a $4.80 exercise price to CEO John Alam, reported as indirect ownership "By Spouse" for director and 10% owner Sylvie Gregoire. The derivative itself was reported at a price of $0.
Who is the reporting person in the CervoMed (CRVO) Form 4 filing?
The reporting person is Sylvie Gregoire, identified as both a director and a 10% owner of CervoMed. The award, however, consists of stock options granted to her spouse, CEO John Alam, and the filing states that Gregoire disclaims beneficial ownership of these securities.
How many CervoMed (CRVO) stock options were granted and at what price?
The filing reports 75,000 stock options relating to CervoMed common stock with a $4.80 exercise price per share. The derivative security itself was recorded at a price of $0, and 75,000 derivative securities are shown as beneficially owned following the transaction.
How do the CervoMed (CRVO) options granted to the CEO’s spouse vest?
The underlying CervoMed common shares vest in 36 equal, or nearly equal, monthly installments. Vesting occurs on the last calendar day of each month over a 36‑month period, beginning on February 28, 2026, according to the Form 4 footnote disclosure.
Does Sylvie Gregoire claim beneficial ownership of the CervoMed (CRVO) options?
No. The Form 4 states that the option grant consists of securities awarded to her spouse, CEO John Alam, and that Sylvie Gregoire disclaims beneficial ownership. The report clarifies it should not be deemed an admission of beneficial ownership for any Section 16 purpose.
What type of transaction code is used in the CervoMed (CRVO) Form 4?
The transaction is coded "A" for an acquisition, indicating a grant, award, or other acquisition of derivative securities. It covers a stock option (right to buy) tied to 75,000 CervoMed common shares, reported as indirect ownership through the reporting person’s spouse.